Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

This Phase 2a study tests a new drug combination — QHRD107 (a CDK9 inhibitor), venetoclax, and azacitidine — in adults with relapsed or refractory acute myeloid leukemia (AML), a fast-moving blood cancer that has come back or stopped responding to previous treatments. Researchers want to see if this combination is safe and effective for these hard-to-treat patients. **You may be eligible if...** - You are 18 or older with AML that has relapsed (come back) or not responded to previous treatment - Your AML failed 2 or more standard treatment courses, came back within 12 months of remission, or has relapsed twice or more - You are in reasonably good health (ECOG score of 0-2) - Your liver and kidney function are adequate - Your white blood cell count is manageable **You may NOT be eligible if...** - You have previously received a CDK9 inhibitor - You have a history of certain blood cancers like CML or MPN, or a specific chromosome abnormality (Ph+ or BCR-ABL) - You have acute promyelocytic leukemia (APL) - You have HIV or active hepatitis B or C - You have had a recent allogeneic stem cell transplant (within 60 days) - You are pregnant or breastfeeding - You have significant active heart problems Talk to your doctor to see if this trial is right for you.